PaediatricsPhase 1/2NCT04771962
Comparison of the Anaesthetic Gases in Maintainance of General Anaesthesia in Paediatrics
A Phase 1/2 study testing DESFLURANE AND SEVOFLURANE in people with Paediatrics and General Anaesthesia, run by Universiti Sains Malaysia at 1 site in Malaysia.
Trial summary
Desflurane and Sevoflurane are one of the modern inhalational anaesthetic agents currently in use in anaesthetic practice. The properties of desflurane that has low blood gas solubility coefficient of 0.47 compared to sevoflurane (0.68) made it more advantageous when used with supraglottic airway in maintaining… Read more about this study
- Who is it for?
- Ages 3 to 12 yearsHealthy volunteers can take part
- Conditions the study is for
- Paediatrics, General Anaesthesia
- What is being tested?
- DESFLURANE AND SEVOFLURANE
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteMalaysia
- Study dates
- 1 Jan 2020to 31 Dec 2021
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 12 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Aged: 3 years to 12 years old.
- ASA (American Society of Anesthesiologist) I
- BMI (body mass index) less than 95 centile according to age, sex, height
- Preoperative assessment shows low risk of aspiration and no features of difficult intubation.
- No history of difficult intubation or history of admission to ICU for airway complication.
- Operation duration less or equal 2 hours using AmbuAuraGain.
Who cannot join
- Parent refusal for study participation to give informed consent.
- Patients who had an upper respiratory tract infection (URTI) within previous 2 weeks or any respiratory disease ( bronchial asthma, hyperactive airway,sleep apnea, chronic lung disease)
- Known susceptibility to malignant hyperthermia (MH)
- History of moderate to severe hepatic dysfunction following anaesthesia with desflurane not otherwise explained.
Trial locations and contacts
1 site in 1 country.
Malaysia1 site
University of Science Malaysia Hospital
Kubang Kerian, Kelantan, 16150
About this study
Official title: Comparing the Efficacy Between Desflurane and Sevoflurane in Miantainance of Spontaneous General Anaesthesia Using Ambu Aura Gain in Paediatrics Patients
Desflurane and Sevoflurane are one of the modern inhalational anaesthetic agents currently in use in anaesthetic practice. The properties of desflurane that has low blood gas solubility coefficient of 0.47 compared to sevoflurane (0.68) made it more advantageous when used with supraglottic airway in maintaining general anaesthesia in paediatrics . It ensures rapid onset and offset of anaesthesia. Rapid recovery profiles especially among pediatric populations is to ensure less complications associated with prolonged recovery of anaesthesia upon emergence from anaesthesia. Nevertherless, desflurane has its drawback which is it can cause airway irritability related to its pungency. Hence, it is not used as an induction anaesthetic agent in paediatrics. This study was done to evaluate the effectiveness of desflurane in comparison to sevoflurane in maintaining spontaneous general anaesthesia in paediatrics population using Ambu AuraGain .
Read the detailed description
Research design:
- Double blinded , randomised controlled trial.
- Involving paediatrics patients underwent elective surgeries requiring general anaesthesia in Hospital Universiti Sains Malaysia, Kubang Kerian.
- The duration of the study is 24 months.
METHODOLOGY
- After Approval from the Ethics Committee of University Sains Malaysia (USM), verbal and written consent will be taken from the patient's parent(s), 1 day prior of the surgery during pre-operative assessment in ward. All medical information of the patient will be kept confidential.
- The study will be conducted to patient age 3 years to 12 years old, with body weight between 10-30kg after excluding patient who has a upper respiratory tract infection or known susceptible to malignant hyperthermia.
- Patients who fulfil the inclusion and exclusion criteria during pre-operative assessment will be randomized into two group using computer generated randomization. The number generated will be placed in the envelope and allocation will be done on the day of the study prior to anaesthesia : S group (sevoflurane maintainance anaesthesia) = 40 and D group ( desflurane maintainance anaesthesia ) = 40.
- Allocation concealment is being applied in this study to prevent selection bias by concealing the allocation sequence until the moment of assessing.
- Participants and the researcher( whom assessing the outcomes ) are blinded during intervention ( double blinded ), where as the anesthetist in charge ( operator ) is not blinded.
- Standard monitoring with non invasive blood pressure , electrocardiography capnography,and peripheral oxygen saturation ( SPO2) will be used.
- Induction of anaesthesia with intravenous fentanyl 2mcg per kg, intravenous propofol of 2mg/kg and 3-4vol% of sevoflurane under 100% O2 mask ventilation.
- The AmbuAuraGain will be used, with standard insertion technique.
- After induction of anaesthesia, inhalation agent will be switch immediately according to group allocation for maintainance of anaesthesia.
- Anaesthesia will be maintained using SEVOFLURANE at MAC of 1.2 to 1.5 for the S group and DESFLURANE at MAC 1.2 to 1.5 for the D group with mixture of oxygen/air mixture for both groups.
- IV Paracetamol 15mg/kg and IV Fentanyl 0.5mcg/kg will be given as intraoperative analgesia.
- Short acting opiod : IV fentanyl 0.5mcg per kg can be given as rescue analgesia.
- At the end of surgery (the last suture put), the inhalational agents will be tapered down and discontinued, 100% oxygen with 6l/min was administered. The Ambu®AuraGain™ will be removed in the operating room once the child is fully awake (i.e: regular breathing, good tidal volume of 6-8ml/kg, gag reflex, grimacing and purposeful movements of the extremities).
- The child then will be monitored in operating theatre recovery area until the modified Aldrete score reached 8.
- Perioperative events in the operating room will be recorded by a blinded investigator. Any adverse events and emergence agitation during recovery will be recorded by a blinded nurse until patient is discharged to ward.
- The first outcome of this study will be the intraoperative hemodynamics during maintainance of anaesthesia.
- Baseline hemodynamic (blood pressure, heart rate, mean arterial pressure) of the patient during pre-intubation will be taken. After successful intubation, patient haemodynamics will be recorded at 10 minutes interval until 60 minutes and also during pre extubation and post extubation.
- Second outcome will be the time of emergence ( the time interval from gas being off to patient awake,i.e: spontaneous eyes opening) , emergence agitation in recovery area, and the respiratory adverse events that occurs during maintainance of anaesthesia and emergence .
- The respiratory events which will be recorded are, (ie: breath holding , bronchospasm, coughing, laryngospasm, copious secretions ( which required suctioning), desaturations ( SpO2 < than 90% ).
SAMPLE SIZE ESTIMATION
Objective 1 : hemodynamic changes ( heart rate)
To estimate the sample size for our study we utilized the G.Power sample size calculator software version 3.1 - Anova : repeated measures . Parametres used in the sample size are :
Effect size f : 0.39 ( for heart rate , Akhtam A. Shoukry et al,2016)
- 0.05 power : 0.80 number of groups: 2 number of measurements: 10 Standard Deviation within each group : 8.97 Mean group 1 : 68.04, mean group 2 : 75.09
Sample size is 32 per group. Estimated sample size with 10% drop out rate : 70
Objective 2 : Emergence time
To estimate the sample size for our study we utilized the PS: Power and Sample Size Calculations software,version 3.0. We applied the independent t-test. Parametres used in the sample size are :
Standard Deviation = 3.9 ( Demirbilek,2004) Mean difference = 3.8 ( expert opinion ) = 0.05 power = 0.80 m = 1 Sample size is 18 per group. Estimated sample size with 10% drop out rate :40
Objective 3 : Coughing on emergence
To estimate the sample size for our study, we utilized the PS: Power and Sample Size Calculations software,version 3.0. We applied the Dichotomous independent , two proportions,uncorrected chi-square test.
Parametres used in the sample size calculations are :
= 0.05, power = 0.80, m = 1, P0 = 0.49 ( proportion of desflurane among patients who did not cough), Paul at al,2010). P1 = 0.8 ( proportion of desflurane among patients who did cough,) expert opinion ).
Sample size is 36 per group.
Estimated sample size with 10% drop out rate : 80
STATISTICAL DATA ANALYSIS
OBJECTIVE 1:
numerical data will be analysed using ANOVA: repeated measures.
OBJECTIVE 2:
Numerical data will be analysed using independent t test.
OBJECTIVE 3:
Categorical data will be analysed using uncorrected chi square test.
- Conditions
- Paediatrics, General Anaesthesia
- Being tested
- DESFLURANE AND SEVOFLURANE
- Keywords
- paediatrics, spontaneous general anaesthesia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DESFLURANE AND SEVOFLURANEDrug
Also called Suprane and Sevoflurane
COMPARING THE EFFICACY IN MAINTAINANCE OF SPONTANEOUS GENERAL ANAESTHESIA USING AMBU AURA GAIN IN PEDIATRIC PATIENTS
| Study group | Role | What they receive |
|---|---|---|
| DESFLURANE | Experimental | desflurane group- this group of patients will be induced with sevoflurane and maintained with desflurane during spontaneous general anaesthesia Receives: Drug: DESFLURANE AND SEVOFLURANE |
| SEVOFLURANE | Active comparator | the controlled group.patients will be induced and maintained with sevoflurane through out spontaneous general anaesthesia. Receives: Drug: DESFLURANE AND SEVOFLURANE |
What is being measured
The primary outcome is the main question the study is designed to answer.
To compare the blood pressure intraoperatively between desflurane and sevoflurane.
by measuring the blood pressure
Measured: up to 18 months
To compare the heart rate intraoperatively between desflurane and sevoflurane.
by measuring the heart rate
Measured: up to 18 months
To compare the mean arterial pressure intraoperatively between desflurane and sevoflurane.
by measuring the mean arterial pressure
Measured: up to 18 months
Secondary outcomes (2)
To compare the emergence time ( interval from gas being off to patient awake).
to time how many minutes
Measured: up to 18 months
To compare the respiratory events intraoperative and post operative
to observe for the signs :breath holding, bronchospasm,coughing, secretions,desaturations
Measured: up to 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2021
- Study start1 Jan 2020
- Primary completion15 Dec 2021
- Study completion31 Dec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for PaediatricsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universiti Sains Malaysia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rhendra Hardy Mohamad Zaini, Universiti Sains Malaysia
- Investigators
- Rhendra Hardy Mohamed Zaini, Principal investigator, University Sains Malaysia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04771962
- Sponsor's protocol ID
- USM/JEPem/18050248
- Status last verified
- Sep 2023
- First submitted
- 4 Nov 2020
- Last updated
- 28 Sep 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Lerman J, Hammer GB, Verghese S, Ehlers M, Khalil SN, Betts E, Trillo R, Deutsch J; MAPS Investigators Group. Airway responses to desflurane during maintenance of anesthesia and recovery in children with laryngeal mask airways. Paediatr Anaesth. 2010 Jun;20(6):495-505. doi: 10.1111/j.1460-9592.2010.03305.x. Epub 2010 Apr 23.
PubMed 20456065Akhtam A. Shoukry, Ayman Abd Laltif,Amr Abd Fattah, Ibrahim Abd Ghani, Mohamed Serag. Isoflurane versus desflurane : hemodynamic parametres and recovery charecteristics:a comparative study.Ain Shams Journal of Anaesthesiology 2016,9:45-51
Demirbilek S, Togal T, Cicek M, Aslan U, Sizanli E, Ersoy MO. Effects of fentanyl on the incidence of emergence agitation in children receiving desflurane or sevoflurane anaesthesia. Eur J Anaesthesiol. 2004 Jul;21(7):538-42. doi: 10.1017/s0265021504007069.
PubMed 15318465White PF, Tang J, Wender RH, Yumul R, Stokes OJ, Sloninsky A, Naruse R, Kariger R, Norel E, Mandel S, Webb T, Zaentz A. Desflurane versus sevoflurane for maintenance of outpatient anesthesia: the effect on early versus late recovery and perioperative coughing. Anesth Analg. 2009 Aug;109(2):387-93. doi: 10.1213/ane.0b013e3181adc21a.
PubMed 19608808Kim EH, Song IK, Lee JH, Kim HS, Kim HC, Yoon SH, Jang YE, Kim JT. Desflurane versus sevoflurane in pediatric anesthesia with a laryngeal mask airway: A randomized controlled trial. Medicine (Baltimore). 2017 Sep;96(35):e7977. doi: 10.1097/MD.0000000000007977.
PubMed 28858134Sethi S, Ghai B, Ram J, Wig J. Postoperative emergence delirium in pediatric patients undergoing cataract surgery--a comparison of desflurane and sevoflurane. Paediatr Anaesth. 2013 Dec;23(12):1131-7. doi: 10.1111/pan.12260. Epub 2013 Sep 19.
PubMed 24102666Davis PJ, Cohen IT, McGowan FX Jr, Latta K. Recovery characteristics of desflurane versus halothane for maintenance of anesthesia in pediatric ambulatory patients. Anesthesiology. 1994 Feb;80(2):298-302. doi: 10.1097/00000542-199402000-00009.
PubMed 8311312Jindal R, Kumra VP, Narani KK, Sood J. Comparison of maintenance and emergence characteristics after desflurane or sevoflurane in outpatient anaesthesia. Indian J Anaesth. 2011 Jan;55(1):36-42. doi: 10.4103/0019-5049.76604.
PubMed 21431051Satyanarayana A, Aparanji K, Gopalakrishna K. Comparison of airway responses, haemodynamics and recovery using sevoflurane and desflurane via laryngeal mask airway in day care paediatric surgeries. J. Evid. Based Med. Healthc. 2017; 4(92), 5559-5563.
Kotwani MB, Malde AD. Comparison of maintenance, emergence and recovery characteristics of sevoflurane and desflurane in pediatric ambulatory surgery. J Anaesthesiol Clin Pharmacol. 2017 Oct-Dec;33(4):503-508. doi: 10.4103/joacp.JOACP_194_16.
PubMed 29416244
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparing the Efficacy Between Desflurane and Sevoflurane in Miantainance of Spontaneous General Anaesthesia Using Ambu Aura Gain in Paediatrics Patients
- ClinicalTrials.gov ID
- NCT04771962
- Acronym / sponsor ID
- USM/JEPem/18050248
- Conditions
- Paediatrics, General Anaesthesia
- Keywords
- paediatrics, spontaneous general anaesthesia
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Universiti Sains MalaysiaUniversity, hospital or other
- Study start
- 1 Jan 2020 (actual)
- Primary completion
- 15 Dec 2021 (actual)
- Study completion
- 31 Dec 2021 (actual)
- First posted
- 25 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Desflurane and Sevoflurane are one of the modern inhalational anaesthetic agents currently in use in anaesthetic practice. The properties of desflurane that has low blood gas solubility coefficient of 0.47 compared to sevoflurane (0.68) made it more advantageous when used with supraglottic airway in maintaining general anaesthesia in paediatrics . It ensures rapid onset and offset of anaesthesia. Rapid recovery profiles especially among pediatric populations is to ensure less complications associated with prolonged recovery of anaesthesia upon emergence from anaesthesia. Nevertherless, desflurane has its drawback which is it can cause airway irritability related to its pungency. Hence, it is not used as an induction anaesthetic agent in paediatrics. This study was done to evaluate the effectiveness of desflurane in comparison to sevoflurane in maintaining spontaneous general anaesthesia in paediatrics population using Ambu AuraGain .
Detailed description
Research design:
- Double blinded , randomised controlled trial.
- Involving paediatrics patients underwent elective surgeries requiring general anaesthesia in Hospital Universiti Sains Malaysia, Kubang Kerian.
- The duration of the study is 24 months.
METHODOLOGY
- After Approval from the Ethics Committee of University Sains Malaysia (USM), verbal and written consent will be taken from the patient's parent(s), 1 day prior of the surgery during pre-operative assessment in ward. All medical information of the patient will be kept confidential.
- The study will be conducted to patient age 3 years to 12 years old, with body weight between 10-30kg after excluding patient who has a upper respiratory tract infection or known susceptible to malignant hyperthermia.
- Patients who fulfil the inclusion and exclusion criteria during pre-operative assessment will be randomized into two group using computer generated randomization. The number generated will be placed in the envelope and allocation will be done on the day of the study prior to anaesthesia : S group (sevoflurane maintainance anaesthesia) = 40 and D group ( desflurane maintainance anaesthesia ) = 40.
- Allocation concealment is being applied in this study to prevent selection bias by concealing the allocation sequence until the moment of assessing.
- Participants and the researcher( whom assessing the outcomes ) are blinded during intervention ( double blinded ), where as the anesthetist in charge ( operator ) is not blinded.
- Standard monitoring with non invasive blood pressure , electrocardiography capnography,and peripheral oxygen saturation ( SPO2) will be used.
- Induction of anaesthesia with intravenous fentanyl 2mcg per kg, intravenous propofol of 2mg/kg and 3-4vol% of sevoflurane under 100% O2 mask ventilation.
- The AmbuAuraGain will be used, with standard insertion technique.
- After induction of anaesthesia, inhalation agent will be switch immediately according to group allocation for maintainance of anaesthesia.
- Anaesthesia will be maintained using SEVOFLURANE at MAC of 1.2 to 1.5 for the S group and DESFLURANE at MAC 1.2 to 1.5 for the D group with mixture of oxygen/air mixture for both groups.
- IV Paracetamol 15mg/kg and IV Fentanyl 0.5mcg/kg will be given as intraoperative analgesia.
- Short acting opiod : IV fentanyl 0.5mcg per kg can be given as rescue analgesia.
- At the end of surgery (the last suture put), the inhalational agents will be tapered down and discontinued, 100% oxygen with 6l/min was administered. The Ambu®AuraGain™ will be removed in the operating room once the child is fully awake (i.e: regular breathing, good tidal volume of 6-8ml/kg, gag reflex, grimacing and purposeful movements of the extremities).
- The child then will be monitored in operating theatre recovery area until the modified Aldrete score reached 8.
- Perioperative events in the operating room will be recorded by a blinded investigator. Any adverse events and emergence agitation during recovery will be recorded by a blinded nurse until patient is discharged to ward.
- The first outcome of this study will be the intraoperative hemodynamics during maintainance of anaesthesia.
- Baseline hemodynamic (blood pressure, heart rate, mean arterial pressure) of the patient during pre-intubation will be taken. After successful intubation, patient haemodynamics will be recorded at 10 minutes interval until 60 minutes and also during pre extubation and post extubation.
- Second outcome will be the time of emergence ( the time interval from gas being off to patient awake,i.e: spontaneous eyes opening) , emergence agitation in recovery area, and the respiratory adverse events that occurs during maintainance of anaesthesia and emergence .
- The respiratory events which will be recorded are, (ie: breath holding , bronchospasm, coughing, laryngospasm, copious secretions ( which required suctioning), desaturations ( SpO2 < than 90% ).
SAMPLE SIZE ESTIMATION
Objective 1 : hemodynamic changes ( heart rate)
To estimate the sample size for our study we utilized the G.Power sample size calculator software version 3.1 - Anova : repeated measures . Parametres used in the sample size are :
Effect size f : 0.39 ( for heart rate , Akhtam A. Shoukry et al,2016)
- 0.05 power : 0.80 number of groups: 2 number of measurements: 10 Standard Deviation within each group : 8.97 Mean group 1 : 68.04, mean group 2 : 75.09
Sample size is 32 per group. Estimated sample size with 10% drop out rate : 70
Objective 2 : Emergence time
To estimate the sample size for our study we utilized the PS: Power and Sample Size Calculations software,version 3.0. We applied the independent t-test. Parametres used in the sample size are :
Standard Deviation = 3.9 ( Demirbilek,2004) Mean difference = 3.8 ( expert opinion ) = 0.05 power = 0.80 m = 1 Sample size is 18 per group. Estimated sample size with 10% drop out rate :40
Objective 3 : Coughing on emergence
To estimate the sample size for our study, we utilized the PS: Power and Sample Size Calculations software,version 3.0. We applied the Dichotomous independent , two proportions,uncorrected chi-square test.
Parametres used in the sample size calculations are :
= 0.05, power = 0.80, m = 1, P0 = 0.49 ( proportion of desflurane among patients who did not cough), Paul at al,2010). P1 = 0.8 ( proportion of desflurane among patients who did cough,) expert opinion ).
Sample size is 36 per group.
Estimated sample size with 10% drop out rate : 80
STATISTICAL DATA ANALYSIS
OBJECTIVE 1:
numerical data will be analysed using ANOVA: repeated measures.
OBJECTIVE 2:
Numerical data will be analysed using independent t test.
OBJECTIVE 3:
Categorical data will be analysed using uncorrected chi square test.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| DESFLURANE | Experimental | Drug: DESFLURANE AND SEVOFLURANEdesflurane group- this group of patients will be induced with sevoflurane and maintained with desflurane during spontaneous general anaesthesia |
| SEVOFLURANE | Active comparator | Drug: DESFLURANE AND SEVOFLURANEthe controlled group.patients will be induced and maintained with sevoflurane through out spontaneous general anaesthesia. |
Who may qualify
- Ages
- 3 to 12 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (6 listed)
- Aged: 3 years to 12 years old.
- ASA (American Society of Anesthesiologist) I
- BMI (body mass index) less than 95 centile according to age, sex, height
- Preoperative assessment shows low risk of aspiration and no features of difficult intubation.
- No history of difficult intubation or history of admission to ICU for airway complication.
Key exclusion criteria (4 listed)
- Parent refusal for study participation to give informed consent.
- Patients who had an upper respiratory tract infection (URTI) within previous 2 weeks or any respiratory disease ( bronchial asthma, hyperactive airway,sleep apnea, chronic lung disease)
- Known susceptibility to malignant hyperthermia (MH)
- History of moderate to severe hepatic dysfunction following anaesthesia with desflurane not otherwise explained.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DESFLURANE AND SEVOFLURANEAlso: Suprane and SevofluraneCOMPARING THE EFFICACY IN MAINTAINANCE OF SPONTANEOUS GENERAL ANAESTHESIA USING AMBU AURA GAIN IN PEDIATRIC PATIENTS | Drug | DESFLURANE, SEVOFLURANE |
Primary outcome
To compare the blood pressure intraoperatively between desflurane and sevoflurane.
Time frame: up to 18 months
by measuring the blood pressure
To compare the heart rate intraoperatively between desflurane and sevoflurane.
Time frame: up to 18 months
by measuring the heart rate
To compare the mean arterial pressure intraoperatively between desflurane and sevoflurane.
Time frame: up to 18 months
by measuring the mean arterial pressure
2 secondary outcomes
To compare the emergence time ( interval from gas being off to patient awake).
Time frame: up to 18 months
To compare the respiratory events intraoperative and post operative
Time frame: up to 18 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2023.
- Background: PubMed 20456065Lerman J, Hammer GB, Verghese S, Ehlers M, Khalil SN, Betts E, Trillo R, Deutsch J; MAPS Investigators Group. Airway responses to desflurane during maintenance of anesthesia and recovery in children with laryngeal mask airways. Paediatr Anaesth. 2010 Jun;20(6):495-505. doi: 10.1111/j.1460-9592.2010.03305.x. Epub 2010 Apr 23.
- BackgroundAkhtam A. Shoukry, Ayman Abd Laltif,Amr Abd Fattah, Ibrahim Abd Ghani, Mohamed Serag. Isoflurane versus desflurane : hemodynamic parametres and recovery charecteristics:a comparative study.Ain Shams Journal of Anaesthesiology 2016,9:45-51
- Background: PubMed 15318465Demirbilek S, Togal T, Cicek M, Aslan U, Sizanli E, Ersoy MO. Effects of fentanyl on the incidence of emergence agitation in children receiving desflurane or sevoflurane anaesthesia. Eur J Anaesthesiol. 2004 Jul;21(7):538-42. doi: 10.1017/s0265021504007069.
- Background: PubMed 19608808White PF, Tang J, Wender RH, Yumul R, Stokes OJ, Sloninsky A, Naruse R, Kariger R, Norel E, Mandel S, Webb T, Zaentz A. Desflurane versus sevoflurane for maintenance of outpatient anesthesia: the effect on early versus late recovery and perioperative coughing. Anesth Analg. 2009 Aug;109(2):387-93. doi: 10.1213/ane.0b013e3181adc21a.
- Background: PubMed 28858134Kim EH, Song IK, Lee JH, Kim HS, Kim HC, Yoon SH, Jang YE, Kim JT. Desflurane versus sevoflurane in pediatric anesthesia with a laryngeal mask airway: A randomized controlled trial. Medicine (Baltimore). 2017 Sep;96(35):e7977. doi: 10.1097/MD.0000000000007977.
- Background: PubMed 24102666Sethi S, Ghai B, Ram J, Wig J. Postoperative emergence delirium in pediatric patients undergoing cataract surgery--a comparison of desflurane and sevoflurane. Paediatr Anaesth. 2013 Dec;23(12):1131-7. doi: 10.1111/pan.12260. Epub 2013 Sep 19.
- Background: PubMed 8311312Davis PJ, Cohen IT, McGowan FX Jr, Latta K. Recovery characteristics of desflurane versus halothane for maintenance of anesthesia in pediatric ambulatory patients. Anesthesiology. 1994 Feb;80(2):298-302. doi: 10.1097/00000542-199402000-00009.
- Background: PubMed 21431051Jindal R, Kumra VP, Narani KK, Sood J. Comparison of maintenance and emergence characteristics after desflurane or sevoflurane in outpatient anaesthesia. Indian J Anaesth. 2011 Jan;55(1):36-42. doi: 10.4103/0019-5049.76604.
- BackgroundSatyanarayana A, Aparanji K, Gopalakrishna K. Comparison of airway responses, haemodynamics and recovery using sevoflurane and desflurane via laryngeal mask airway in day care paediatric surgeries. J. Evid. Based Med. Healthc. 2017; 4(92), 5559-5563.
- Background: PubMed 29416244Kotwani MB, Malde AD. Comparison of maintenance, emergence and recovery characteristics of sevoflurane and desflurane in pediatric ambulatory surgery. J Anaesthesiol Clin Pharmacol. 2017 Oct-Dec;33(4):503-508. doi: 10.4103/joacp.JOACP_194_16.
- Individual participant dataSharing planned: No
Related trials for Paediatrics
Not yet recruiting
Feasibility of a Robot-Guided Active Play Intervention for Children With Cerebral Palsy
Cerebral Palsy
RecruitingPhase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Seizures, Lennox Gastaut Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
RecruitingObservational study
Psychological Benefits of a Normalized Camping Experience for Children With Cancer
Pediatric Cancer
Not yet recruitingObservational study
AI-assisted Tracheal Intubation in Children
Intubation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rhendra Hardy Mohamed Zaini principal investigator
University Sains Malaysia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing DESFLURANE AND SEVOFLURANE in people with Paediatrics and General Anaesthesia, run by Universiti Sains Malaysia at 1 site in Malaysia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To compare the blood pressure intraoperatively between desflurane and sevoflurane. (time frame: up to 18 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04771962, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2023.